Cayuga Biotech
Bridgewater
About Cayuga Biotech
Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $8.2M
- Funding stage: Seed
- Last round: Grant (Dec 2025)
- Website: cayugabio.tech
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cayuga-biotech-75715 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.